Biotech | October 11, 2025
Dr. Jitendra Singh inaugurates 10th Annual "Cell and Gene Therapy" symposium
Several technologies for hemoglobinopathies are being transferred to commercial partners
Several technologies for hemoglobinopathies are being transferred to commercial partners
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Subscribe To Our Newsletter & Stay Updated
